May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Bevacizumab for Treatment of Macular Edema Secondary to Retinal Vein Occlusion
Author Affiliations & Notes
  • A. E. Hoeh
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • K. B. Schaal
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • A. Scheuerle
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • S. Dithmar
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • Footnotes
    Commercial Relationships A.E. Hoeh, None; K.B. Schaal, None; A. Scheuerle, None; S. Dithmar, None.
  • Footnotes
    Support Gertrud Kusen Foundation (Di 2007)
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 307. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. E. Hoeh, K. B. Schaal, A. Scheuerle, S. Dithmar; Bevacizumab for Treatment of Macular Edema Secondary to Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2007;48(13):307.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the efficacy of bevacizumab (AvastinTM) in patients with macular edema due to retinal vein occlusion.

Methods:: Prospective study. After informed consent patients with persistent macular edema (>350µm) due to retinal vein occlusion receive intravitreal bevacizumab (2.5mg/0.1ml) every 6 weeks until macular edema resolves. Ophthalmic examination, visual acuity (ETDRS) and Stratus OCTTM are performed at baseline, 1 week after injection and on a monthly basis. Fluorescein angiography and regular medical check-up are also performed.

Results:: 34 patients (18 CRVO, 16 BRVO) have been included in the study so far with a mean follow-up of 30 ± 6 weeks. The intravitreous injections were very well tolerated with no intraocular or systemic adverse events. On last visit, mean central retinal thickness decreased by 403µm compared to baseline. Visual acuity could be stabilised in all patients. 62% of patients gained at least 3 lines. 21% of patients gained ≥ 6 lines.

Conclusions:: Repeated intravitreal injection of bevacizumab 2.5mg did not reveal any short term safety concerns. Treatment resulted in a significant decrease in macular edema and improvement of visual acuity. Follow-up is ongoing to determine the durability of this favorable outcome.

Keywords: growth factors/growth factor receptors • vascular occlusion/vascular occlusive disease • edema 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×